

(English version)

**Question for written answer E-003388/25
to the Commission
Gerald Hauser (Pfe)
(3 September 2025)**

Subject: US finally rescinds authorisation for insufficiently tested COVID-19 vaccines

In its answer to Question E-002126/2025 ⁽¹⁾, the Commission recently confirmed that ‘a comprehensive data dossier is not yet available’ for the COVID-19 vaccines. In the 20 November 2020 purchase agreement concluded with Pfizer, the Commission and all EU Member States signed to explicitly say that they ‘acknowledge that the long-term effects and efficacy of the Vaccine are not currently known and that there may be adverse effects of the Vaccine that are not currently known.’ As a result, every vaccinated person in the EU has been relegated to the role of experimental guinea pig. On 27 August 2025, US Secretary of Health Robert Kennedy Jr said that the emergency use authorisation for COVID-19 vaccines had been rescinded. Meanwhile, in the EU, these vaccinations are still offered and recommended unconditionally to the entire population, including pregnant women, babies and children.

1. Will the Commission now also rescind its COVID-19 vaccine authorisations for the population as a whole?
2. Who in the Commission is now responsible for vaccine damage, especially among healthy people with no pre-existing conditions?
3. What does the Commission have to say about the continuing lack of substantial data on the safety and effectiveness of COVID-19 vaccines, as the FDA has now officially confirmed?

Submitted: 3.9.2025

**Answer given by Mr Várhelyi on behalf of the European Commission
(10 November 2025)**

In line with the applicable European legislation, the conditional marketing authorisations granted for the COVID-19 vaccines Comirnaty, Spikevax and Nuvaxovid were converted into standard marketing authorisations on 10 October 2022, 5 October 2022 and 4 July 2023, respectively, once the specific obligations imposed on the marketing authorisation holders were fulfilled.

The COVID-19 vaccine Bimervax was granted a standard marketing authorisation, based on a full dossier application, on 30 March 2023.

Like for all medicines authorised in the EU, the European Medicines Agency (EMA) and national authorities continuously monitor the COVID-19 vaccine safety assessing all available data, including EudraVigilance ⁽¹⁾ reports, scientific literature and studies to determine if there is a causality between an adverse effect and a medicine and take action as appropriate.

There is so far no evidence justifying the revocation of the marketing authorisations for any COVID-19 vaccine authorised in the EU. On the contrary, there is an unprecedented amount of supportive data on the efficacy and safety of COVID-19 vaccines authorised in the EU, which has been gathered following the use of the vaccines in hundreds of millions of people worldwide.

The contracts for the purchase of COVID-19-vaccines contain clauses that outline in detail the obligations and responsibilities of the contractual parties involved regarding potential losses, damages, liabilities, or legal claims arising from the COVID-19 vaccines.

However, claims for damages resulting from harmful events suffered, including from healthy people with no pre-existing conditions, by the use of COVID-19 vaccines are subject to the rules laid down in the legislation of Member States.

¹ https://www.europarl.europa.eu/doceo/document/E-10-2025-002126-ASW_EN.html

⁽¹⁾ <https://www.ema.europa.eu/en/human-regulatory-overview/research-development/pharmacovigilance-research-development/eudravigilance>.